Fingolimod affects gene expression profile associated with LPS-induced memory impairment

Experimental Brain Research

Volumn 232, Issue 11, 2014, Pages 3687-3696

  Omidbakhsh, Rana ^a   Rajabli, Banafshe ^b   Nasoohi, Sanaz ^b   Khallaghi, Behzad ^b   Mohamed, Zahurin ^a   Naidu, Murali ^a   Ahmadiani, Abolhassan ^a,b   Dargahi, Leila ^b  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

FTY720; Gene profiling; Neuroinflammation; Sphingosine 1 phosphate

Indexed keywords

FINGOLIMOD; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; CASPASE 3; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1BETA; NERVE PROTEIN; PROPANEDIOL DERIVATIVE; SPHINGOSINE; TRANSCRIPTOME; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DENTATE GYRUS; DRUG EFFICACY; FEMALE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HEMISPHERE; MALE; MEMORY DISORDER; NERVE CELL; NONHUMAN; PASSIVE AVOIDANCE TEST; PERFORMANCE; RAT; ANALOGS AND DERIVATIVES; ANIMAL; AVOIDANCE BEHAVIOR; BRAIN; CHEMICALLY INDUCED; DARK ADAPTATION; DISEASE MODEL; DRUG ADMINISTRATION; DRUG ADMINISTRATION ROUTE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MEMORY DISORDERS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; WISTAR RAT;

ANIMALS; AVOIDANCE LEARNING; BRAIN; CASPASE 3; DARK ADAPTATION; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE EXPRESSION REGULATION; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MALE; MEMORY DISORDERS; NERVE TISSUE PROTEINS; PROPYLENE GLYCOLS; RATS; RATS, WISTAR; SPHINGOSINE; TRANSCRIPTOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84919847602     PISSN: 00144819     EISSN: 14321106     Source Type: Journal    
DOI: 10.1007/s00221-014-4052-4     Document Type: Article

References (53)

1. Allende ML, Bektas M, Lee BG, Bonifacino E, Kang J, Tuymetova G, Chen W, Saba JD, Proia RL (2011) Sphingosine-1-phosphate lyase deficiency produces a pro-inflammatory response while impairing neutrophil trafficking. J Biol Chem 286:7348–7358
2. Alvarez SE, Harikumar KB, Hait NC, Allegood J, Strub GM, Kim EY, Maceyka M, Jiang H, Luo C, Kordula T (2010) Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature 465:1084–1088
3. Araujo D, Lapchak P, Robitaille Y, Gauthier S, Quirion R (1988) Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer’s disease. J Neurochem 50:1914–1923
4. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277:21453–21457
5. Chalfant CE, Spiegel S (2005) Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling. J Cell Sci 118:4605–4612
6. Ching LK, Mompoint F, Guderian JA, Picone A, Orme IM, Coler RN, Reed SG, Baldwin SL (2011) Transcriptional profiling of TLR-4/7/8-stimulated guinea pig splenocytes and whole blood by bDNA assay. J Immunol Methods 373:54–62
7. Cohen JA, Barkhof F, Comi G, Hartung H-P, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New Engl J Med 362:402–415
8. Corbyn Z (2013) New set of Alzheimer’s trials focus on prevention. Lancet 381:614–615
9. Cyster JG (2005) Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 23:127–159
10. Cyster JG (2010) B cell follicles and antigen encounters of the third kind. Nat Immunol 11:989–996
11. Czech B, Pfeilschifter W, Mazaheri-Omrani N, Strobel MA, Kahles T, Neumann-Haefelin T, Rami A, Huwiler A, Pfeilschifter J (2009) The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia. Biochem Biophys Res Commun 389:251–256
12. Deogracias R, Yazdani M, Dekkers MP, Guy J, Ionescu MCS, Vogt KE, Barde Y-A (2012) Fingolimod, a sphingosine-1 phosphate receptor modulator increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Proc Natl Acad Sci USA 109:14230–14235
13. Donahue DA, Dougherty EJ, Meserve LA (2004) Influence of a combination of two tetrachlorobiphenyl congeners (PCB 47; PCB 77) on thyroid status, choline acetyltransferase (ChAT) activity, and short-and long-term memory in 30-day-old Sprague–Dawley rats. Toxicology 203:99–107
14. Eklind S, Hagberg H, Wang X, Sävman K, Leverin A-L, Hedtjärn M, Mallard C (2006) Effect of lipopolysaccharide on global gene expression in the immature rat brain. Pediatr Res 60:161–168
15. El Alwani M, Wu BX, Obeid LM, Hannun YA (2006) Bioactive sphingolipids in the modulation of the inflammatory response. Pharmacol Ther 112:171–183
16. Espinosa-Oliva AM, de Pablos RM, Herrera AJ (2013) Intracranial injection of LPS in rat as animal model of neuroinflammation. Microglia 1041:295–305
17. Estrada-Bernal A, Palanichamy K, Chaudhury AR, Van Brocklyn JR (2012) Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma. Neuro-oncology 14:405–415
18. Fibiger HC (1991) Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence. Trends Neurosci 14:220–223
19. Finney CA, Hawkes CA, Kain DC, Dhabangi A, Musoke C, Cserti-Gazdewich C, Oravecz T, Liles WC, Kain KC (2011) S1P is associated with protection in human and experimental cerebral malaria. Mol Med 17:7–8
20. Foster CA, Howard LM, Schweitzer A, Persohn E, Hiestand PC, Balatoni B, Reuschel R, Beerli C, Schwartz M, Billich A (2007) Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Expe Ther 323:469–475
21. Gao F, Liu Y-F, Li X-W, Wang Y, Wei D, Jiang W (2012) Fingolimod (FTY720) inhibits neuroinflammation and attenuates spontaneous convulsions in lithium-pilocarpine induced status epilepticus in rat model. Pharmacol Biochem Behav 103:187–196
22. Garman RH (2011) Histology of the central nervous system. Toxicol Pathol 39:22–35
23. Ge PF, Luo TF, Zhang JZ, Chen DW, Luan YX, Fu SL (2008) Ischemic preconditioning induces chaperone hsp70 expression and inhibits protein aggregation in the CA1 neurons of rats. Neurosci Bull 24:288–296
24. Hemmati F, Dargahi L, Nasoohi S, Omidbakhsh R, Mohamed Z, Naidu M, Ahmadiani A (2013) Neurorestorative effect of FTY720 in a rat model of Alzheimer’s disease: comparison with memantine. Behav Brain Res 252:415–421
25. Huang W-C, Nagahashi M, Terracina KP, Takabe K (2013) Emerging role of sphingosine-1-phosphate in Inflammation, cancer, and lymphangiogenesis. Biomolecules 3:408–434
26. Jenne CN, Enders A, Rivera R, Watson SR, Bankovich AJ, Pereira JP, Xu Y, Roots CM, Beilke JN, Banerjee A (2009) T-bet-dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow. J Exp Med 206:2469–2481
27. Kása P, Rakonczay Z, Gulya K (1997) The cholinergic system in Alzheimer’s disease. Prog Neurobiol 52:511–535
28. King DL, Arendash GW, Crawford F, Sterk T, Menendez J, Mullan MJ (1999) Progressive and gender-dependent cognitive impairment in the APP-transgenic mouse model for Alzheimer’s disease. Behav Brain Res 103:145–162
29. Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM (2005) Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer’s disease. J Neurosci 25:8843–8853
30. Kolesnick RN (1987) 1,2-Diacylglycerols but not phorbol esters stimulate sphingomyelin hydrolysis in GH3 pituitary cells. J Biol Chem 262:16759–16762
31. Lee JW, Lee YK, Yuk DY, Choi DY, Ban SB, Oh KW, Hong JT (2008) Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. J Neuroinflamm 5:37–51
32. Lee KD, Chow WN, Sato-Bigbee C, Graf MR, Graham RS, Colello RJ, Young HF, Mathern BE (2009) FTY720 reduces inflammation and promotes functional recovery after spinal cord injury. J Neurotrauma 26:2335–2344
33. Lee JE, Kim SY, Jeong YM, Yun HY, Baek KJ, Kwon NS, Park KC, Kim DS (2011) The regulatory mechanism of melanogenesis by FTY720, a sphingolipid analogue. Exp Dermatol 20:237–241
34. Lisman J, Schulman H, Cline H (2002) The molecular basis of CaMKII function in synaptic and behavioural memory. Nat Rev Neurosci 3:175–190
35. Liu X, Yao M, Li N, Wang C, Zheng Y, Cao X (2008) CaMKII promotes TLR-triggered proinflammatory cytokine and type I interferon production by directly binding and activating TAK1 and IRF3 in macrophages. Blood 112:4961–4970
36. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427:355–360
37. Matsuda S, Minowa A, Suzuki S, Koyasu S (1999) Differential activation of c-Jun NH2-terminal kinase and p38 pathways during FTY720-induced apoptosis of T lymphocytes that is suppressed by the extracellular signal-regulated kinase pathway. J Immunol 162:3321–3326
38. Mehan S, Meena H, Sharma D, Sankhla R (2011) JNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer’s and various neurodegenerative abnormalities. J Mol Neurosci 43:376–390
39. Miron VE, Schubart A, Antel JP (2008) Central nervous system-directed effects of FTY720 (fingolimod). J Neurol Sci 274:13–17
40. Mufson EJ, Ginsberg SD, Ikonomovic MD, DeKosky ST (2003) Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. J Chem Neuroanat 26:233–242
41. Noda H, Takeuchi H, Mizuno T, Suzumura A (2013) Fingolimod phosphate promotes the neuroprotective effects of microglia. J Neuroimmunol 256:13–18
42. Nozaki K, Nishimura M, Hashimoto N (2001) Mitogen-activated protein kinases and cerebral ischemia. Mol Neurobiol 23:1–19
43. Okazaki T, Bell R, Hannun Y (1989) Sphingomyelin turnover induced by vitamin D3 in HL-60 cells Role in cell differentiation. J Biol Chem 264:19076–19080
44. O’Neill LA (2006) Targeting signal transduction as a strategy to treat inflammatory diseases. Nat Rev Drug Discov 5:549–563
45. Pandey A, Mann M (2000) Proteomics to study genes and genomes. Nature 405:837–846
46. Pereira C, Schaer DJ, Bachli EB, Kurrer MO, Schoedon G (2008) Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of activated protein C and interleukin-10. Arterioscler Thromb Vasc Biol 28:504–510
47. Rivera J, Proia RL, Olivera A (2008) The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol 8:753–763
48. Sato M, Tanaka N, Hata N, Oda E, Taniguchi T (1998) Involvement of the IRF family transcription factor IRF-3 in virus-induced activation of IFN-β gene. FEBS Lett 425:112–116
49. Sell KM, Crowe SF, Kent S (2001) Lipopolysaccharide induces memory-processing deficits in day-old chicks. Pharmacol Biochem Behav 68:497–502
50. Um MY, Ahn JY, Kim MK, Ha TY (2012) Sesaminol glucosides protect β-amyloid induced apoptotic cell death by regulating redox system in SK-N-SH. Cells Neurochem Res 37:689–699
51. Vartanian KB, Stenzel-Poore MP (2010) Toll-like receptor tolerance as a mechanism for neuroprotection. Transl Stroke Res 1:252–260
52. Viña J, Lloret A (2010) Why women have more Alzheimer’s disease than men: gender and mitochondrial toxicity of amyloid-β peptide. J Alzheimers Dis 20:527–533
53. Wei Y, Yemisci M, Kim HH, Yung LM, Shin HK, Hwang SK, Guo S, Qin T, Alsharif N, Brinkmann V (2011) Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol 69:119–129